Lilly to buy private biotech Disarm Therapeutics for up to $1.36bnEli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of Share XLilly to buy private biotech Disarm Therapeutics for up to $1.36bnhttps://pharmaphorum.com/news/lilly-to-buy-private-biotech-disarm-therapeutics-for-up-to-1-36bn/
NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
Roche hits back at Novartis with new data for MS drug OcrevusRoche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Share XRoche hits back at Novartis with new data for MS drug Ocrevushttps://pharmaphorum.com/news/roche-hits-back-at-novartis-with-new-data-for-ms-drug-ocrevus/
Mission successful for Novartis after FDA approves ofatumumab in MSIt’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the Share XMission successful for Novartis after FDA approves ofatumumab in MShttps://pharmaphorum.com/news/mission-successful-for-novartis-after-fda-approves-ofatumumab-in-ms/
Teva shares slide as it faces illegal kickback charges from US governmentShares in Teva were down sharply this week after the US Department of Justice filed a complaint that Share XTeva shares slide as it faces illegal kickback charges from US governmenthttps://pharmaphorum.com/news/teva-shares-slide-as-it-faces-illegal-kickback-charges-from-us-government/
Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionSanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to Share XSanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionhttps://pharmaphorum.com/news/sanofi-adds-btk-inhibitors-to-pipeline-with-3-68bn-principia-biopharma-acquisition/
NICE says no to Novartis’ Mayzent in secondary progressive MSThere isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the Share XNICE says no to Novartis’ Mayzent in secondary progressive MShttps://pharmaphorum.com/news/nice-says-no-to-novartis-mayzent-in-secondary-progressive-ms/
Accessibility app wins Novartis multiple sclerosis innovation prizeCanadian start-up AccessNow has won first prize in a Novartis competition to find technological ways to help people Share XAccessibility app wins Novartis multiple sclerosis innovation prizehttps://pharmaphorum.com/news/accessibility-app-wins-novartis-multiple-sclerosis-innovation-prize/
Royalty Pharma plans largest IPO of the year so farRoyalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. Share XRoyalty Pharma plans largest IPO of the year so farhttps://pharmaphorum.com/news/royalty-pharma-plans-largest-ipo-of-the-year-so-far/
